BASIC COMPOSITION FOR PRODUCING A BIOLOGICALLY ACTIVE AGENT

Abstract

The invention relates to biotechnology, pharmacy, cosmetology and veterinary medicine, and can be used in the manufacture of therapeutic, prophylactic, cosmetic, and sanitary and hygienic products such as sprays for air treatment, as well as gels, balms, lotions and liquids for impregnating antiseptic and immune-enhancing wipes, which do not cause side effects.

The technical problem solved by the proposed technical solution consists in increasing the aggregative stability and improving the organoleptic properties of the composition of essential oils and phytoextracts during dilution, storage, pressure increase, freezing while maintaining biological activity. The basic alcoholic-based composition for the preparation of a biologically active agent for the treatment of the human environment includes combinations of essential oils and phytoextracts at a total amount of up to 48%. Plants from the Labiatae and Compositae families rich in terpenoids, flavonoids, carotenoids and anthocyans are used as a source of essential oils and phytoextracts.

The proposed basic formulation of the composition is used to obtain agents for treating air of the indoor space by means of aerosol dispensers.

The finished products retain their biological activity during storage and use.

Claims

1. A basic composition for the preparation of a biologically active agent for the treatment of human environment, the composition comprising essential oils and phytoextracts taken in a ratio of 2:1 in an alcoholic solvent, wherein the essential oils present at a total content of 20 to 34 wt % and represent a combination of eucalyptus essential oil and essential oils of plants of the Labiatae and Compositae families, and the phytoextracts represent a combination of extracts from pine and plants of the Labiatae and Compositae families rich in terpenoids, flavonoids, carotenoids and anthocyans.

2. The basic composition according to claim 1, wherein a combination of oils from plants of 1) the Labiatae family selected from the group including: monarda, hyssop, sage, mint, lavender, basil, rosemary, oregano, thyme; and 2) the Compositae family selected from the group including: maral root, yarrow, marigold, wormwood, each independently at 2 to 14 wt %, is used as essential oils.

3. The basic composition according to claim 1, wherein a combination of extracts from plants of the Labiatae family selected from the group including: sage, rosemary, thyme, oregano, motherwort, basil, skullcap, spikenard; and Compositae family selected from the group including: calendula, dandelion, cornflower, yarrow, beggarticks, chamomile, burdock, echinacea, each independently at 1 to 12 wt %, is used as phytoextracts.

4. The basic composition according to claim 1, wherein the alcoholic solvent is selected from the group including ethyl alcohol, isopropyl alcohol, propyl alcohol.

5. The basic composition according to claim 1, further comprising a fragrance at 1-5 wt % of the composition.

6. The basic composition according to claim 5, wherein the fragrance is selected from perfume and cosmetic compositions or aromatic essential oils.

7. The basic composition according to claim 6, wherein the aromatic essential oils are selected from mint, maral root or lavender essential oils.

Description

THE BEST MODE OF IMPLEMENTATION OF THE INVENTION

[0022] Examples of the formulation of the basic composition, in wt.%:

EXAMPLE 1

[0023]

TABLE-US-00001 Essential oils: total content 32.0 eucalyptus 10.0 sage 8.0 monarda 7.0 hyssop 5.0 maral root 2.0 Phytoextracts: total content 16.0 pine 9.0 oregano 3.0 echinacea 2.0 skullcap 2.0 Fragrance 1.5 Ethyl alcohol balance

[0024] The composition for use in aerosol dispensers with a propellent.

EXAMPLE 2

[0025]

TABLE-US-00002 Essential oils: total content 30.0 eucalyptus 14.0 marigold 9.0 thyme 3.0 oregano 2.0 lavender 2.0 Phytoextracts: total content 15.0 pine 8.0 beggarticks 3.0 calendula 2.0 chamomile 2.0 Fragrance 2.0 Isopropyl alcohol balance

[0026] The composition is used in aerosol dispensers.

EXAMPLE 3

[0027]

TABLE-US-00003 Essential oils: total content 24.0 eucalyptus 5.0 thyme 3.0 maral root 8.0 rosemary 2.0 lavender 3.0 mint 3.0 Phytoextracts: total content 12.0 pine 5.0 yarrow 2.0 sage 2.0 burdock 3.0 Fragrance 4.0 Ethyl alcohol balance

[0028] Basic composition for preparing liposomal formulations.

EXAMPLE 4

[0029]

TABLE-US-00004 Essential oils: total content 22.0 eucalyptus 2.0 sage 2.0 lavender 14.0 hyssop 2.0 basil 2.0 Phytoextracts: total content 11.0 pine 3.0 motherwort 2.0 cornflower 2.0 spikenard 2.0 sage 2.0 Fragrance 4.0 Propyl alcohol balance

[0030] The composition for preparing liposomal concentrates and aerosol dispensers.

EXAMPLE 5

[0031]

TABLE-US-00005 Essential oils: total content 20.0 eucalyptus 3.0 maral root 5.0 mint 3.0 sage 5.0 oregano 2.0 wormwood 2.0 Phytoextracts: total content 10.0 pine 4.0 burdock 2.0 yarrow 2.0 wormwood 2.0 Fragrance 3.0 Ethyl alcohol balance

TABLE-US-00006 TABLE 1 Physicochemical characteristics of the compositions Stability to the addition of Odor special characterization No./No. to dilution additives Density Color and assessment 1 High 1:0.3 0.91 Dark Harsh 4 1:3:66 yellow spicy 2 High 1:0.1 0.915 Greenish Fresh, 4 1:3 yellow harsh 3 Medium  1:0.04 0.920 Ocher Light 5 1:2 yellow grassy 4 High 1:0.3 0.900 Yellow Lavender 4 1:4 5 Medium 1:0.5 0.91 Green Fresh, 5 1:1 floral

[0032] Organoleptic characteristics were determined by performing tests on a group of volunteers among office employees (n=40 people aged from 27 to 65 years).

[0033] A score of 5 points was given to an agent that 100% of the participants liked; 4 points—to an agent that 70% of the participants liked; 3 points—to a formulation that 50% of the participants liked. As a reference product an agent TAGETON was used which has proven high bioactivity (RU patent No. 2452470 —the closest prior art), which received 3 points for organoleptic characteristics (only 50% of the participants liked the smell).

[0034] Aggregative stability was determined by the resistance of the composition to the formation of turbidity or bottom precipitate, as well as stratification and other visual changes during storage, freezing, and dilution.

TABLE-US-00007 TABLE 2 Characterization of stability of the compositions Composition clarity 1 2 3 4 5 Initial 0 0 0 0 0 After a no/change no/change no/change no/change no/change month/year of storage After no/change no/change no/change no/change no/change freezing Dispersity high high high high high when spraying Color Dark Dark Greenish Ocher Yellowy yellow yellow yellow yellow green Biological +++ +++ +++ +++ +++ activity during shelf life 0 - clear liquid according to visual assessment by three experts*. *the assessment is carried out in glass tubes: the inspection is conducted in daylight and a test is used (text with different fonts in the background).

[0035] The proposed basic formulation of the composition is used to obtain agents for the treatment of air of the indoor space by means of aerosol dispensers.

[0036] To obtain an agent for the treatment of air of the indoor space by means of trigger sprayers, ultrasonic humidifiers, as well as separator-type air washes, the proposed composition is used as a “premix”, as a raw component in the preparation of liposomes for the finished product. The finished products retain biological activity during shelf life.

[0037] To test the antimicrobial activity of the composition in vitro (on Petri dishes), the same was converted into a water-soluble form, for example, a liposomal one, and the bacteriostatic effect was assessed using standard microbiological methods on fungi and bacteria. Table 3 provides some data obtained from the tests of the antimicrobial activity of the formulations against antibiotic-resistant bacterial strains.

TABLE-US-00008 TABLE 3 Antimicrobial activity of the compositions Resistance Formulation Strain Source to AMD 1 2 3 4 5 Acinetobacter human AMC AMS +++ +++ ++ + +/− baumannii (endotracheal CEF CTX B-120 aspirate) CTA CAZ CPZ CPS PIT FEP IMI CIP CM GEN TOB AMI THR NIT Klebsiella environment AMP +++ ++ + ++ − pneumoniae (water) M-9 Klebsiella human AZR CAZ ++ ++ +++ + +/− pneumoniae (surgical CEF NET PIT ISV-3 wound) Pseudomonas human TCA TCC + ++ + − − aeruginosa (bronchial PIP PIT FEP B-38/14 lavage) IMI MER PEF GEN IZE TOB AMI THR CTZ MIN Pseudomonas human IMI MER + − + − − aeruginosa (endotracheal THR MIN B-1957 aspirate) Staphylococcus human COL ++ +++ + + +/− aureus ATCC 25923 Staphylococcus bird, head COL DOC ++ + + + − pasteuri sinuses ERI TET Tsarev Salmonella bird, liver TET ++ ++ − + − enterica Lipetsk Salmonella bird, liver AMC AMP ++ + +/− +/− − enterica DOC ERI Chamzinka TET TIL Note: AMD—antimicrobial drugs; AMP—ampicillin; AMC—amoxicillin/clavulanic acid; AMS—amoxicillin-sulbactam; CEF—cefuroxime; CEX—cefoxitin; CTX—cefotaxime; CTA, etc.—ceftriaxone; CAZ—ceftazidime; CPZ—cefoperazone; TCA—ticarcillin; TCC—ticarcillin-clavulanic acid; CPS—cefoperazone-sulbactam; PIP—piperacillin; PIT—piperacillin/tazobactam; FEP—cefepime; ERM—ertapenem, AZR—aztreonam; IMI— imipenem; MER—meropenem; DOC—doxycycline; TGC—tigecycline; CIP—ciprofloxacin; ENR—enrofloxacin; TET—tetracycline; PEF—pefloxacin; CM—chloramphenicol; GEN—gentamicin; IZE—izepamycin; TOB—tobramycin; AMI—amikacin; CTZ—co-trimoxazole; THR—trimethoprim; ERI—eriprim; LIN—lincomycin; NET—netilmicin; PHO—phosphomycin; NIT—nitrofurantoin; MIN—minocycline; COL—colistin.

[0038] The reduction of microbial contamination of the air was assessed using standard microbiological methods by taking air samples for selective media for microbial growth in the office space before and after using the agents. After the use of the agents there was a decrease in the number of microorganisms by 1.5-2.5 times per m.sup.3.

[0039] The effect of the biologically active agent on human performance was determined by assessing the speed of performing work over a certain period of time using Schulte tables before using the agent and 10 minutes after using it. The tests were carried out three times (3 days in a row, at the end of the working day). In a study on a group of volunteers among 20 office employees aged from 30 to 50 years it was found that after using the agents a person spends, on average, 5.4 seconds less to perform a task than usual, when no agents based on the proposed compositions are used.

INDUSTRIAL APPLICABILITY

[0040] The invention can be used in the field of biotechnology, pharmacy, cosmetology and veterinary medicine. It can be used in the manufacture of therapeutic, prophylactic, cosmetic, and sanitary and hygienic products such as sprays for air treatment, as well as gels, balms, lotions and liquids for soaking antiseptic and immune-enhancing wipes having no side effects.